# Digging Deep into Alzheimer Disease: How Electron Microscopy Helps Elucidating Its Pathogenesis

**Authors:** Sveva Dallere, Antonio Migheli, Alessandro Vercelli

PMC · DOI: 10.1007/s10571-026-01676-z · Cellular and Molecular Neurobiology · 2026-02-20

## TL;DR

Electron microscopy reveals detailed subcellular changes in Alzheimer's disease, helping to understand its causes and develop better treatments.

## Contribution

This paper reviews how advanced electron microscopy techniques provide comprehensive insights into Alzheimer's pathology across multiple experimental models.

## Key findings

- Electron microscopy reveals subcellular changes like Aβ plaques and Tau aggregates in Alzheimer's disease.
- Advanced EM techniques like cryo-EM and vEM offer near-atomic resolution and 3D reconstructions of AD pathology.
- EM studies highlight roles of synapses, mitochondria, and inflammation in Alzheimer's progression.

## Abstract

Alzheimer disease (AD), first described by Alzheimer and Perusini in the early twentieth century, is a devastating neurodegenerative disorder without a definitive cure. Unraveling the subcellular alterations underlying AD is essential to elucidate disease mechanisms, track progression, link cellular abnormalities to functional deficits, and develop therapeutic strategies aimed at preventing, slowing or reverting the disease course. Electron microscopy (EM) has been pivotal in this field since the 1960s, when Terry and Kidd characterized the ultrastructure of amyloid-beta (Aβ) deposits and paired helical filaments (PHFs) composed of hyperphosphorylated tau. Over the decades, conventional transmission and scanning EM have been complemented by advanced approaches such as volume EM (vEM), cryo-electron microscopy (cryo-EM), and cryo-electron tomography (cryo-ET). These techniques enable three-dimensional reconstructions, minimize fixation artifacts, and provide near-native, near-atomic resolution insights into AD pathology. EM has also revealed critical contributions of other subcellular compartments to AD pathogenesis, including synapses, mitochondria, lysosomes, the blood–brain barrier, iron deposits, and inflammatory machinery. Importantly, EM studies extend beyond human tissue, encompassing animal models, cell cultures, and synthetic assemblies, thereby allowing cross-system comparisons that highlight conserved pathological features. By integrating data from diverse experimental settings, EM provides a uniquely comprehensive view of the AD subcellular landscape. This makes it an indispensable tool not only for dissecting disease mechanisms but also for guiding the rational design of therapeutic molecules with potential disease-modifying effects. This review synthesizes the state of knowledge on EM-based studies of AD, emphasizing their central role in advancing both mechanistic understanding and translational approaches.

Overview of electron microscopy approaches in AD research. Various experimental models, including human brain tissue, cell cultures, and animal models, are analyzed using TEM, SEM, cryo-EM, CLEM and vEM. Subsequent segmentation and analyses allow investigation of neuropathological features in AD, including Aβ plaques, Tau aggregates, synaptic alterations, mitochondrial dysfunction, neuroinflammation, autophagy deficits, BBB disruption, and iron accumulation. This image was created with BioRender.

## Linked entities

- **Proteins:** MAPT (microtubule associated protein tau)
- **Diseases:** Alzheimer disease (MONDO:0004975)

## Full-text entities

- **Genes:** App (amyloid beta precursor protein) [NCBI Gene 11820] {aka Abeta, Abpp, Adap, Ag, Cvap, E030013M08Rik}, CANX (calnexin) [NCBI Gene 821] {aka CNX, IP90, P90}, APOE (apolipoprotein E) [NCBI Gene 348] {aka AD2, APO-E, ApoE4, LDLCQ5, LPG}, MAPT (microtubule associated protein tau) [NCBI Gene 4137] {aka DDPAC, FTD1, FTDP-17, MAPTL, MSTD, MTBT1}, AIF1 (allograft inflammatory factor 1) [NCBI Gene 199] {aka AIF-1, IBA1, IRT-1, IRT1}, Psen1 (presenilin 1) [NCBI Gene 19164] {aka Ad3h, PS-1, PS1, S182}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, CTSD (cathepsin D) [NCBI Gene 1509] {aka CLN10, CPSD, HEL-S-130P}, APPL1 (adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1) [NCBI Gene 26060] {aka APPL, DIP13alpha, MODY14}, PSEN1 (presenilin 1) [NCBI Gene 5663] {aka ACNINV3, AD3, CMD1U, FAD, PS-1, PS1}, RMDN1 (regulator of microtubule dynamics 1) [NCBI Gene 51115] {aka CGI-90, FAM82B, RMD-1, RMD1}, SLIT2 (slit guidance ligand 2) [NCBI Gene 9353] {aka SLIL3, Slit-2}, MFGE8 (milk fat globule EGF and factor V/VIII domain containing) [NCBI Gene 4240] {aka BA46, EDIL1, HMFG, HsT19888, MFG-E8, MFGM}
- **Diseases:** pTau (MESH:C536599), structural abnormalities (MESH:C566527), prion diseases (MESH:D017096), amyloid angiopathy (MESH:C538248), PHFs (MESH:C579880), Iron Deposits (MESH:D000090463), NFTs (MESH:D055956), synaptic degeneration (MESH:D012183), neuronal dysfunction (MESH:D009461), ischemia (MESH:D007511), metabolic abnormalities (MESH:D008659), EM (MESH:D028361), traumatic injury (MESH:D014947), neurodegeneration (MESH:D019636), inflammation (MESH:D007249), CCH (MESH:D006521), cerebral amyloidopathies (MESH:D002547), BBB (MESH:C536830), atrophy (MESH:D001284), Neuroinflammation (MESH:D000090862), AD-related diseases (MESH:D000544), neurotoxic (MESH:D020258), corticobasal degeneration (MESH:D000088282), DS (MESH:D004314), microangiopathy (MESH:D014652), ischemic (MESH:D002545), amyloid (MESH:C000718787), dementia (MESH:D003704), sleep fragmentation (MESH:D012892), eye degeneration (MESH:D009410), amyloidosis (MESH:D000686), cognitive decline (MESH:D003072), amyloid plaques (MESH:D058225), memory loss (MESH:D008569), Pick disease (MESH:D020774), synaptic dysfunction (MESH:C536122), glucose hypometabolism (MESH:D018149), progressive supranuclear palsy (MESH:D013494), necrosis (MESH:D009336), gliosis (MESH:D005911), vascular damage (MESH:D057772), tauopathies (MESH:D024801), infections (MESH:D007239)
- **Chemicals:** Iron (MESH:D007501), cholesterol (MESH:D002784), iron oxide (MESH:C000499), SDS (MESH:D012967), copper (MESH:D003300), magnetite (MESH:D052203), oxygen (MESH:D010100), zinc (MESH:D015032), metal (MESH:D008670), Lecanemab (MESH:C000612089), rapamycin (MESH:D020123), lipid (MESH:D008055), paraformaldehyde (MESH:C003043), ATP (MESH:D000255), calcium (MESH:D002118), glutaraldehyde (MESH:D005976), gallium (MESH:D005708), DAB (MESH:C000469), Fe3O4 (-), aluminum (MESH:D000535), sulfur (MESH:D013455), lipofuscin (MESH:D008062)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Mus musculus (house mouse, species) [taxon 10090], Drosophila melanogaster (fruit fly, species) [taxon 7227], Danio rerio (leopard danio, species) [taxon 7955], Macaca mulatta (rhesus macaque, species) [taxon 9544], Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Mutations:** C322S, E280A, P301S, P301L, E22G, C322A
- **Cell lines:** mAPP — Homo sapiens (Human), Transformed cell line (CVCL_B2RV), SH-SY5Y — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0019), C20 — Homo sapiens (Human), Crohn disease, Induced pluripotent stem cell (CVCL_WT77), PC 12 — Rattus norvegicus (Rat), Rat adrenal gland pheochromocytoma, Cancer cell line (CVCL_0481)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12967783/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12967783/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12967783/full.md

---
Source: https://tomesphere.com/paper/PMC12967783